Compound tirzepatide vs Mounjaro: what the science says

What did @mrsdwithglee actually say?

She compared her personal experience on compounded tirzepatide versus brand-name Mounjaro across three areas: appetite suppression, food noise, and side effects. Her headline claim is that Mounjaro hit harder on appetite, but she actually prefers compounded tirzepatide because, in her words, "I work out every day now and I need to eat enough." She also said compounded tirzepatide "blows Mounjaro out of the water" on side effects and energy levels, and that she even cut her caffeine intake since switching. These are personal, anecdotal observations, not a controlled comparison. To her credit, she frames them that way. She is not claiming one is medically superior or therapeutically equivalent to the other. That framing matters a lot right now, legally and scientifically.

Does the science back this up?

Partially, but with real caveats. The appetite suppression difference she describes is biologically plausible, but not for the reasons most people assume. Tirzepatide, whether brand or compounded, is a dual GIP and GLP-1 receptor agonist. The registered clinical trials, specifically the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), showed dramatic appetite reduction and weight loss at higher doses. What the science cannot tell us is whether her compounded version contains the same active ingredient at the same potency as Mounjaro. Compounded tirzepatide is not FDA-approved and is not required to demonstrate bioequivalence. The FDA has explicitly stated that compounded drugs are not the same as FDA-approved drugs. So when she notices a difference in appetite suppression or side effects between the two, she cannot attribute that to tirzepatide behaving differently. It may reflect differences in formulation, excipients, concentration, or even dosing accuracy from the compounding pharmacy.

What did they get wrong (or right)?

She got the food noise piece roughly right. Both GLP-1 and GIP receptor activity are associated with reduced reward-driven eating behavior. Research from van Bloemendaal et al. (2014, Diabetes Care) and more recent neuroimaging work suggests GLP-1 receptor agonists reduce activity in brain regions associated with food reward. Tirzepatide's dual mechanism may amplify this. Her observation that both "do a phenomenal job of taking all those unnecessary cravings away" is consistent with the pharmacology. Where she goes wrong, or at least unsupported, is the blanket claim that compounded tirzepatide has better side effects. There is no clinical data comparing compounded and brand-name tirzepatide head-to-head. Her side effect experience could reflect dose differences, formulation differences, individual adaptation over time, or simple placebo-adjacent effects from preferring one product over another. She is presenting an N-of-1 experience as a general insight, and 23,000 viewers may take that as evidence it will apply to them.

What should you actually know?

The FDA placed compounded tirzepatide on its shortage list, which temporarily allowed compounding pharmacies to produce it legally. That status has been contested and updated. As of early 2025, the FDA declared the tirzepatide shortage resolved, meaning most compounded versions are no longer legally permitted under the shortage exemption. This is not a small detail. Anyone currently getting compounded tirzepatide should verify their pharmacy's legal standing. Beyond legality, compounded products carry real quality risks. A 2023 FDA analysis found serious adverse events linked to compounded GLP-1 products, including incorrect dosing and contamination. Her energy improvement and reduced caffeine use are interesting anecdotes, but GIP receptor activity does have metabolic effects that could plausibly influence energy, though that mechanism is not well-characterized in humans yet. Do not take her experience as a dosing or switching guide.